John H. Johnson has been named chief executive officer of Savient Pharmaceuticals, Inc., effective January 31, 2011. Mr. Johnson will also serve as a member of the board of directors. Paul Hamelin, Savient’s president and most senior officer will continue in his current role throughout a transition period and will then leave the company to pursue other interests. Mr. Johnson has significant biotechnology business experience having served as a senior vice president of Eli Lilly and Co. ...